Sight Sciences, Inc. reported $83M of revenue over the trailing twelve months, +9.3% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $83M (to Q2 2026). Net income: −$30M, trailing twelve months to Q2 2026. Free cash flow: −$24M, trailing twelve months to Q2 2026. Operating margin: −34%, trailing twelve months to Q2 2026.

SGHTSight Sciences, Inc.

Healthcare

$8.46+144% 1Y

$8.46

$3.2052 weeks$9.34

SGHT as reported

Sight Sciences, Inc. reported $83M of revenue over the trailing twelve months, +9.3% on the year before. 10 reported series are charted on this page, each one as filed.

$83M

Revenue, trailing twelve months · to Q2 2026 · +9.3% against the twelve months before

Net income: −$30M
Net income · −39% year on year · trailing twelve months to Q2 2026
Free cash flow: −$24M
Free cash flow · +4.4% year on year · trailing twelve months to Q2 2026
Operating margin: −34%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SGHT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$83M	+9.3%	Q2 2026
Net income	−$30M	−39%	Q2 2026
EPS	−$0.56	−42%	Q2 2026
Gross margin	88%	n/a	Q2 2026
Operating margin	−34%	n/a	Q2 2026
Net margin	−37%	n/a	Q2 2026
ROE	−64%	n/a	Q2 2026
ROA	−34%	n/a	Q2 2026
ROIC	−210%	n/a	Q2 2026
Free cash flow	−$24M	+4.4%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.